Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV)
|
Add to portfolio |
|
|
|
| Price: |
$0.82
| | Metrics |
| OS: |
3.11
|
M
| |
-81
|
% ROE
|
| Market cap: |
$2.56
|
M
| |
-552
|
% ROIC
|
|
Net cash:
|
$10.7
|
M
| |
$3.45
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($9.8)
|
M
| |
|
|
|
EBIT
|
($9.8)
|
M
| |
|
|
| EPS |
($4.99)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | -11.4 | -2.3 | 0.0 | 0.0 |
| Revenue growth | | | | -100.0% | 402.9% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | -25.5 | -49.2 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 14.1 | 46.9 | 0.0 | 0.0 |
| Gross margin | | | | | -124.0% | -2069.7% | | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 5.2 | 4.4 | 3.9 | 5.6 | 4.9 | 11.1 | 12.6 | 10.1 |
| General and administrative | 5.4 | 5.5 | 5.2 | 5.9 | 7.8 | 13.5 | 11.5 | 12.3 |
| EBITA | -10.7 | -9.9 | -9.1 | -11.5 | -12.8 | -24.6 | -24.0 | -22.4 |
| EBITA margin | | | | | 111.8% | 1084.1% | | |
| Amortization of intangibles | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT | -10.7 | -9.9 | -9.1 | -11.5 | -12.8 | -24.6 | -24.1 | -22.4 |
| EBIT margin | | | | | 112.0% | 1084.8% | | |
| Pre-tax income | -10.5 | -9.9 | -9.1 | -11.8 | -23.4 | -26.7 | -23.4 | -33.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -10.5 | -9.9 | -9.1 | -11.8 | -23.4 | -26.7 | -23.4 | -33.3 |
| Net margin | | | | | 205.5% | 1179.8% | | |
| |
| Diluted EPS | ($6.83) | ($7.48) | ($1.31) | ($35.28) | ($140.81) | ($20.29) | ($0.76) | ($1.26) |
| Shares outstanding (diluted) | 1.5 | 1.3 | 6.9 | 0.3 | 0.2 | 1.3 | 31.0 | 26.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|